ClinicalTrials.gg
CompletedNCT02426541DERISCUpdated Feb 5, 2018Results posted

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Dapagliflozin and Placebo in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in Finland. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
113th of 180
55 · median 82
Started
2015
with 14 others
Phase 4
77 of 180
7 open now
Registered
59th of 180
by date
Lead sponsor
72 of 180
AstraZeneca

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 113th largest by enrollment, is one of 15 that started in 2015, is one of 77 in phase 4, and was the 59th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 35 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Dapagliflozin
  • Placebo
  • Insulin resistance
  • Insulin sensitivity
04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Provision of signed prior to any study specific procedures.
  2. Female or male aged 35 to 70 years inclusive with suitable veins for cannulation or repeated venipuncture
  3. Type 2 Diabetes mellitus defined as of ≥ 6.5% and ≤ 10.5%.
  4. Stable (≥ 3 months) T2D treatment with metformin and/or metformin+dipeptidyl peptidase-4 inhibitors (DPP-IV)
  5. (BMI) ≤ 40 kg/m2.
  6. Female subjects must be of non-, meeting at least one of the following criteria:

    1. Hysterectomized females
    2. women, defined as women who have not had a menstrual period within 1 year

Main Exclusion Criteria:

  1. Any condition that is with MRI such as, but not limited to, having a pacemaker or claustrophobia.
  2. Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.
  3. Recent Cardiovascular Events in a patient:

    • Acute Coronary Syndrome (ACS) within 2 months prior to enrolment
    • Hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment
    • Acute Stroke or (TIA) within two months prior to enrolment
    • Less than two months post coronary artery revascularization
  4. Congestive heart failure defined as (NYHA) class IV, unstable or acute congestive heart failure.
  5. Blood pressure at enrolment: Systolic BP ≥165 mm Hg and/or diastolic BP ≥100 mm Hg
  6. Any illness, medical or surgical procedure or trauma within 4 weeks of the first administration of the product.
  7. On insulin, GLP-1 or other oral antidiabetic drug treatment (metformin or both metformin and DPP-IV allowed) or using other medications known to affect glucose metabolism.
  8. Any clinically significant abnormalities in physical examination, Electrocardiography () or clinical chemistry results as judged by the investigator. The following specific exclusion criteria apply to the selected Clinical Chemistry results:

    1. \<60mL/min (estimated with Cockroft-Gault formula).
    2. Severe hepatic insufficiency and/or significant abnormal liver function defined as (AST) >3x (ULN) and/or alanine aminotransferase (ALT) >3x ULN.
    3. Total (TB) >2.0 mg/dL (34.2 µmol/L).
  9. Body weight loss greater than 5% within 3 months prior to Visit 1.
  10. Previous PET scan
  11. History of or presence of (as found at Visit 1) any clinically significant disease, disorder or condition which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Dapagliflozin

    Dapagliflozin Once Daily 10 mg

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo

    Matching placebo for Dapagliflozin Once Daily 10 mg

    Drug: Placebo

Interventions

  • Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

    Also known as: Forxiga, Farxiga

  • DrugPlacebo

    Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

06

What researchers measure

Primary outcomes

  1. Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake

    Adjusted change from baseline in skeletal muscle insulin-stimulated gluocose uptake (umol/min/kg)

    Time frame: From baseline to Week 8

Secondary outcomes

  1. Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake

    Change in adipose tissue insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET

    Time frame: Baseline to Week 8

  2. Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8

    Adjusted change in liver insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET

    Time frame: Baseline to Week 8

07

Results

Posted Feb 5, 2018

Participant flow

A total of 55 subjects were enrolled and 32 subjects were randomised and treated. One participant was withdrawn prior to study completion. Thirty-one participants completed the study and attended all visits.

Participant flow — Overall Study
MilestoneDapagliflozin 10 MGPlacebo
Started1616
Completed1516
Not completed10
Withdrew: Protocol violation10

Outcome measures

SecondaryAdjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake

Change in adipose tissue insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · umol/min/kg
Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake
umol/min/kgDapagliflozin 10 MGPlacebo
Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake1.04 ± 1.50-0.64 ± 1.36
Statistical analysis
  • Dapagliflozin 10 MG vs Placebo · ANCOVA · p = 0.3794 · Mean difference (final values): 1.68 · 95% CI -2.18 to 5.54Adjusted for sex and baseline
SecondaryAdjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8

Adjusted change in liver insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · umol/min/kg
Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8
umol/min/kgDapagliflozin 10 MGPlacebo
Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 80.27 ± 1.741.59 ± 1.52
Statistical analysis
  • Dapagliflozin 10 MG vs Placebo · ANCOVA · p = 0.5317 · Mean difference (final values): -1.32 · 95% CI -5.60 to 2.96Adjusted for sex and baseline
PrimaryAdjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake

Adjusted change from baseline in skeletal muscle insulin-stimulated gluocose uptake (umol/min/kg)

Time frame:
From baseline to Week 8
Reported as:
Least squares mean · umol/min/kg
Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake
umol/min/kgDapagliflozin 10 MGPlacebo
Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake0.28 ± 1.230.28 ± 1.13
Statistical analysis
  • Dapagliflozin 10 MG vs Placebo · ANCOVA · p = 0.9984 · Mean difference (final values): -0.0030 · 95% CI -3.07 to 3.07Adjusted for sex and baseline

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 10 MG—0/16 (0%)6/16 (37.5%)
Placebo—0/16 (0%)7/16 (43.8%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDapagliflozin 10 MGPlacebo
PolyuriaRenal and urinary disorders4/160/16
Respiratory tract infectionInfections and infestations1/162/16
Balanitis candidaInfections and infestations1/160/16
ConstipationGastrointestinal disorders1/160/16
NauseaGastrointestinal disorders0/161/16
AsteniaGeneral disorders0/161/16
ThirstGeneral disorders1/160/16
Blood glucose decreasedInvestigations1/160/16
ArthralgiaMusculoskeletal and connective tissue disorders0/161/16
Joint swellingMusculoskeletal and connective tissue disorders0/161/16

Baseline characteristics

Population represents the full analysis set which includes all randomised subjects who received at least one dose of study with a non-missing baseline value and at least one post-baseline value for at least one primary or secondary efficacy variable during the double-blind period.

Age, Continuous
Age, Continuous(years)Dapagliflozin 10 MGPlaceboTotal
Mean62.1 ± 8.459.9 ± 7.461.0 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 10 MGPlaceboTotal
Female246
Male131225
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dapagliflozin 10 MGPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White151631
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Research Site
    Turku, Finland
09

References and documents

Publications

  • Latva-Rasku A, Honka MJ, Kullberg J, Mononen N, Lehtimaki T, Saltevo J, Kirjavainen AK, Saunavaara V, Iozzo P, Johansson L, Oscarsson J, Hannukainen JC, Nuutila P. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019 May;42(5):931-937. doi: 10.2337/dc18-1569. Epub 2019 Mar 18. PubMed 30885955 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Apr 2016, 13 months.

Results were first posted in Feb 2018, 1 year 9 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2015
First posted
Apr 27, 2015
StartActual
Mar 23, 2015
Primary completionActual
Apr 28, 2016
CompletionActual
Apr 28, 2016
Results first posted
Feb 5, 2018
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02426541
Lead sponsor
AstraZeneca
Collaborators
Antaros Medical, Bioventure Hub, 43183 Mölndal, Sweden
Responsible party
Sponsor
First posted
Apr 27, 2015
Start date
Mar 23, 2015
Primary completion
Apr 28, 2016
Completion
Apr 28, 2016
Results posted
Feb 5, 2018
Last update
Feb 5, 2018

Study contacts

Pirjo Nuutila, MD, PhD, Professor
principal investigator · Turku PET Centre, Turku, Finland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion